Accordingly, pursuant to the provisions of 21 U.S.C. 811(d)(4)(B), the Administrator of the DEA hereby orders that propylhexedrine be, and it hereby is, decontrolled.

In accordance with the provisions of 21 U.S.C. 811(a), this action is a formal rulemaking "on the record after the opportunity for a hearing". Such proceedings are conducted pursuant to the provisions of 5 U.S.C. 556 and 557 and, as such, have been exempted from the consultation requirements of Executive Order 12291 (46 FR 13193).

Pursuant to 5 U.S.C. 609(b), the Administrator certifies that the decontrol of propylhexedrine will have no significant economic impact upon entities whose interests must be considered under the Regulatory Flexibility Act (Pub. L. 98-375).

Decontrol of a substance relieves manufacturers and other registrants of the regulatory requirements relating to controlled substances.

This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12212, and it has been determined that this matter does not have sufficient federalism implications to warrant preparation of a Federalism Assessment.

List of Subjects in 21 CFR Part 1308

Administrative practice and procedure, Drug traffic control, Narcotics and prescription drugs.

Under the authority vested in the Attorney General by section 201(a) of the CSA (21 U.S.C. 811(a)) and delegated to the Administrator of the DEA by Department of Justice Regulations (28 CFR 0.100), the Administrator hereby proposes that title 21 CFR, part 1308 be amended as follows:

PART 1308—[AMENDED]

1. The authority citation for title 21, CFR part 1308 continues to read as follows:

Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted.

§ 1308.15 [Amended]

2. Section 1308.15 is amended by removing paragraph (d)(1) and redesignating paragraph (d)(2) as (d)(1).


Robert C. Bonner,
Administrator of Drug Enforcement.

[FR Doc. 91-28888 Filed 12-2-91; 8:45 am]

BILLING CODE 4410-06-M